Standard Glass Lining Technology Ltd Q2FY26: From Reactors to ROFL — When an Engineering Company Turns IPO Star and Starts Shopping Worldwide

Engineering Profits, Pharmaceutical Clients, and a Glass-Lined Ego the Size of a Reactor

---

1. At a Glance

Standard Glass Lining Technology Ltd (SGLTL) has become that overachieving engineer in your batch who somehow cracked both the GRE and the UPSC. With a market cap of ₹3,360 crore and a P/E of 47.2x, the company sits comfortably in the premium valuation club of India’s industrial manufacturing sector, while quietly pumping out reactors, dryers, and lined pipes that end up in nearly every pharmaceutical and chemical factory worth its solvents.

In Q2FY26 (Sept 2025), SGLTL reported revenue of ₹183 crore, up 10.5% YoY, and profit of ₹20.2 crore, growing 3.6% YoY — proving that even reactors take time to heat up. The quarterly OPM stood steady at 16%, keeping margins glassy and smooth. With an ROCE of 16.5% and ROE of 11.6%, the company’s efficiency is decent, though not quite Michelin-star-worthy.

Despite clocking profits for years, they pay zero dividend — apparently preferring to reinvest in more plants than in investors’ patience. Debt stands at ₹137 crore, debt-to-equity at a modest 0.18x, and interest coverage of 9.24x. Working capital days ballooned to 272 — a polite way of saying customers are treating invoices like long-term savings schemes.

Still, the company’s story is anything but boring: new acquisitions, overseas subsidiaries, and reactor sales that could power half of India’s pharma labs. Let’s dig in.

---

2. Introduction

Imagine a company that literally manufactures the equipment in which other companies make money. That’s Standard Glass Lining Technology Ltd for you — the unsung hero of India’s pharmaceutical and chemical infrastructure. Incorporated in 2012, this Hyderabad-based firm designs, fabricates, and installs the very reactors and dryers where pharma giants like Aurobindo and Natco cook up their billion-rupee molecules.

Now, this isn’t your average steel-and-sparks business. It’s a specialized engineering outfit dealing in glass-lined reactors, PTFE-lined pipes, and Agitated Nutsche Filter Dryers (ANFDs) — items that sound like spells from a chemical wizard’s handbook.

The company operates eight factories spread across 400,000 sq. ft. in Telangana, and turns out more than 300 pieces of high-tech equipment a month — including 100 reactors and 9,000 PTFE-lined pipes. In FY24, pharma clients contributed 81.8% of revenues, with chemicals and others filling in the rest.

Despite being only a decade old, SGLTL already counts industry behemoths among its 347 clients, and has 13 out of its top 20 customers locked in for more than three years. That’s not client retention — that’s industrial marriage.

But beneath all the shiny reactors and glossy IPO brochures, the real question is: Can SGLTL maintain its momentum without cracking under operational pressure like — well — glass?

---

3. Business Model – WTF Do They Even Do?

If India’s chemical and pharma industries were a Bollywood movie, SGLTL would be the reliable supporting actor who ensures the hero looks good on screen. The company manufactures and installs equipment that handle highly corrosive, high-pressure, and high-temperature processes — think of it as the protective armor around dangerous reactions.

Here’s the business breakdown:

• Reaction Systems (57% of revenue): These are the reactors where the magic happens. From glass-lined reactors (AE & BE types) to stainless and nickel-alloy reactors, these are the cauldrons of chemistry.
• Storage, Separation & Drying Systems (30%): Fancy dryers and filters that make sure pharma companies don’t literally blow up their labs. ANFDs, RCVDs, and vacuum dryers dominate this segment.
• Plant Engineering & Services (13%): The “EPC” style turnkey solutions. If you’re a pharma plant starting from scratch, SGLTL will design, assemble, and hand you the keys — like a real estate agent with a chemical degree.
• PTFE-Lined Pipes & Fittings: Designed for corrosive materials. Their durability makes even relationships look weak in comparison.
• Heat Exchangers: The company recently entered the glass-lined heat exchanger segment through a 20-year tie-up with Japan’s AGI Group, eyeing a ₹2,000 crore market. When you partner with Japan, you’re basically importing precision with a side of sushi.

So, in short — they build the machines that make the medicines that make us believe in science.

---

4. Financials Overview

Quarterly Performance Snapshot (₹ crore)

Metric	Q2FY26 (Sep 2025)	Q2FY25 (Sep 2024)	Q1FY26 (Jun 2025)	YoY %	QoQ %
Revenue	183	165	173	10.5%	5.8%
EBITDA	29	34	30	-14.7%	-3.3%
PAT	20.2	19.5	21.0	3.6%	-3.8%
EPS (₹)	1.01	1.07	1.05	-5.6%	-3.8%

Annualized EPS ≈ ₹4.04 → P/E ≈ 41.8x at ₹169 CMP

Commentary:
Sales up, margins stable, profit mildly better — the Q2FY26 report card reads “consistent but could participate more in class.” While growth is modest, the steady 16% OPM shows that management knows how to operate reactors and balance sheets with equal finesse.

---

5. Valuation Discussion – Fair Value Range Only

Let’s crunch a few educational numbers (because valuation is just glorified math with optimism):

1. P/E Method:
   EPS (TTM) = ₹3.63
   Industry P/E = 34.8
   → Fair Value Range: ₹126 – ₹200
2. EV/EBITDA Method:
   EV = ₹3,477 crore
   EBITDA (TTM) =